ELDN · Eledon Pharmaceuticals, Inc. · Executive Compensation
$2.62
+0.00 (+0.00%)
At close · Nov 3
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plan, the Company expects that, within the next twelve months, its existing cash, cash equivalents, short-term investments and other available resources will not be sufficient to fund its planned operations and satisfy its obligations as they become due unless it obtains additional financing. Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside the Company's control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$212.90M
Shares
81.26M
Volume · Nov 3
403.17K
Avg daily vol (3M)
913.96K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David-Alexandre Gros | Chief Executive Officer | $3,216,148 |
| David-Alexandre C. Gros | Chief Executive Officer | $3,216,148 |
| Steven Perrin | President and Chief Scientific Officer | $1,696,284 |
| Paul Little | Chief Financial Officer | $1,592,943 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David-Alexandre C. Gros | Chief Executive Officer | $5,644,970 |
| David-Alexandre Gros | Chief Executive Officer | $5,644,970 |
| Steven Perrin | President and Chief Scientific Officer | $4,571,222 |
| Paul Little | Chief Financial Officer | $3,090,335 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David-Alexandre Gros | Chief Executive Officer | $2,553,153 |
| David-Alexandre C. Gros | Chief Executive Officer | $2,553,153 |
| Steven Perrin | President and Chief Scientific Officer | $1,540,583 |
| Paul Little | Chief Financial Officer | $1,321,176 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David-Alexandre C. Gros | Chief Executive Officer | $1,118,493 |
| David-Alexandre Gros | Chief Executive Officer | $1,118,493 |
| Paul Little | Chief Financial Officer | $1,057,392 |
| Steven Perrin | President and Chief Scientific Officer | $1,049,577 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Paul Little | Chief Financial Officer | $2,307,958 |
| Bryan Smith | General Counsel, Corporate Secretary and Compliance Officer | $1,682,736 |
| David-Alexandre Gros | Chief Executive Officer | $747,504 |
| David-Alexandre C. Gros | Chief Executive Officer | $747,504 |
| Steven Perrin | President and Chief Scientific Officer | $566,813 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David-Alexandre C. Gros | Chief Executive Officer | $7,419,307 |
| David-Alexandre Gros | Chief Executive Officer | $7,419,307 |
| Steven Perrin | Ph.D.^(^^3)^ President and Chief Scientific Officer | $3,113,055 |
| Gregory J. Flesher | Former Chief Executive Officer | $2,415,586 |
| Jon Kuwahara | — | $1,218,294 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | Former Chief Executive Officer | $842,664 |
| Catherine C. Turkel | President | $597,657 |
| Senior Vice | President of Finance and Administration | $392,850 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | Chief Executive Officer | $943,081 |
| Catherine C. Turkel | President | $625,501 |
| Senior Vice | President of Finance and Administration | $429,581 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Walter Ogier | Director | Retired | 2024-07-10 |
| June Lee | Class I Director | Appointed | 2024-07-10 |
| Steven Perrin | Class I Director | Appointed | 2024-07-10 |
| Allan Douglas Kirk, MD, PhD, FACS | director | Appointed | 2023-10-02 |
| James Robinson | director | Appointed | 2023-09-13 |
| Jan Hillson | Class III Director | Appointed | 2023-06-22 |
| David-Alexandre C. Gros | Class III Director | Appointed | 2023-06-22 |
| Gary A. Lyons | Board of Directors | Retired | 2023-05-01 |
Leadership
- David-Alexandre "DA" C. Gros, M.D. CEO, Board Member
- David-Alexandre C. Gros CEO, Board Member
- David-Alexandre C. Gros, M.D. CEO, Board Member
- David-Alexandre Gros CEO, Board Member
- Jon Kuwahara CEO
- Paul Little CFO, Chief Accounting Officer
- Bryan Smith General Counsel
- Allan D. Kirk Board Member
- Allan Douglas Kirk, MD, PhD, FACS Board Member
- James Robinson Board Member
- Jan Hillson Board Member
- Jan Hillson, M.D. Board Member
- John S. McBride Board Member
- June Lee Board Member
- June Lee, M.D. Board Member
- Steven N. Perrin, Ph.D. Board Member
- Steven Perrin Board Member
- Steven Perrin, Ph.D. Board Member
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
45 filings
44 filers
Visit website
Investor relations